Literature DB >> 19048259

[Pathogenesis of retinopathy of prematurity].

M Heckmann1.   

Abstract

Retinopathy of prematurity (ROP) is a vascular disease of the eye unique to preterm infants. The distinctive feature of ROP is that is an illness of the still-maturing organism. Thus, an understanding of the normal fetal development of the retina is fundamental to understanding the pathogenesis of ROP. Animal models of ROP differ in important attributes, a fact that is important for interpretation of results. However, all models have in common the finding that ROP is a biphasic disease. In the first phase, relative hyperoxia results in vaso-obliteration and vessel loss. The second phase is characterized by hypoxia-induced neovascularization resulting in retinal detachment and blindness. Oxygen-dependent vascular endothelial growth factor (VEGF) and oxygen-independent insulin-like growth factor (IGF-1) have been identified as important factors in the pathogenesis of ROP. These findings suggest new therapeutic approaches. Substitution of IGF-1 during the first phase of the disease may help prevent vessel loss, and administration of anti-angiogenic substances during the second phase may prevent pathological neovascularization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048259     DOI: 10.1007/s00347-008-1789-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  42 in total

1.  Experimental approach to the pathogenesis of retrolental fibroplasia. I. Changes of the eye induced by exposure of newborn mice to concentrated oxygen.

Authors:  L J GYLLENSTEN; B E HELLSTROM
Journal:  Acta Paediatr Suppl       Date:  1954

2.  Retinopathy of prematurity: clinical implications of retinal development.

Authors:  F L Kretzer; H M Hittner
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

3.  Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor.

Authors:  Takeshi Kita; Yasuaki Hata; Kumiko Kano; Muneki Miura; Shintaro Nakao; Yoshihiro Noda; Hiroaki Shimokawa; Tatsuro Ishibashi
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 4.  Retinopathy of prematurity.

Authors:  Jing Chen; Lois E H Smith
Journal:  Angiogenesis       Date:  2007-02-27       Impact factor: 9.596

5.  HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.

Authors:  Masanobu Morita; Osamu Ohneda; Toshiharu Yamashita; Satoru Takahashi; Norio Suzuki; Osamu Nakajima; Shimako Kawauchi; Masatsugu Ema; Shigeki Shibahara; Tetsuo Udono; Koji Tomita; Makoto Tamai; Kazuhiro Sogawa; Masayuki Yamamoto; Yoshiaki Fujii-Kuriyama
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

6.  Elevated erythropoietin mRNA and protein concentrations in the developing human eye.

Authors:  Shrena Patel; Michael J Rowe; Sally A Winters; Robin K Ohls
Journal:  Pediatr Res       Date:  2008-04       Impact factor: 3.756

7.  Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity.

Authors:  Janet R McColm; Steve Cunningham; Jean Wade; Kofi Sedowofia; Balazs Gellen; Tarun Sharma; Neil McIntosh; Brian W Fleck
Journal:  Pediatr Res       Date:  2003-10-15       Impact factor: 3.756

8.  Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.

Authors:  E A Pierce; E D Foley; L E Smith
Journal:  Arch Ophthalmol       Date:  1996-10

9.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

10.  Genetic polymorphisms and retinopathy of prematurity.

Authors:  Richard W I Cooke; Jo A Drury; Roger Mountford; David Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-06       Impact factor: 4.799

View more
  4 in total

1.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

Review 2.  Bioactive lipids and pathological retinal angiogenesis.

Authors:  Khaled Elmasry; Ahmed S Ibrahim; Samer Abdulmoneim; Mohamed Al-Shabrawey
Journal:  Br J Pharmacol       Date:  2018-11-19       Impact factor: 8.739

3.  Twin-twin transfusion syndrome as a possible risk factor for the development of retinopathy of prematurity.

Authors:  Andreas Gschließer; Eva Stifter; Thomas Neumayer; Elisabeth Moser; Andrea Papp; Guido Dorner; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-11       Impact factor: 3.117

4.  670nm photobiomodulation as a novel protection against retinopathy of prematurity: evidence from oxygen induced retinopathy models.

Authors:  Riccardo Natoli; Krisztina Valter; Marconi Barbosa; Jane Dahlstrom; Matt Rutar; Alison Kent; Jan Provis
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.